<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="publisher-id">nss</journal-id>
      <journal-id journal-id-type="pmc">nss</journal-id>
      <journal-title-group>
        <journal-title>Nature and Science of Sleep</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1179-1608</issn>
      <publisher>
        <publisher-name>Dove</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">34234594</article-id>
      <article-id pub-id-type="pmc">8243594</article-id>
      <article-id pub-id-type="publisher-id">311801</article-id>
      <article-id pub-id-type="doi">10.2147/NSS.S311801</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Searching for Novel Candidate Biomarkers of RLS in Blood by Proteomic Analysis</article-title>
        <alt-title alt-title-type="running-authors">Mondello et al</alt-title>
        <alt-title alt-title-type="running-title">Mondello et al</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Mondello</surname>
            <given-names>Stefania</given-names>
          </name>
          <xref ref-type="aff" rid="aff0001">
            <sup>1</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5008-6944</contrib-id>
          <name>
            <surname>Kobeissy</surname>
            <given-names>Firas H</given-names>
          </name>
          <xref ref-type="aff" rid="aff0002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mechref</surname>
            <given-names>Yehia</given-names>
          </name>
          <xref ref-type="aff" rid="aff0002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>Jingfu</given-names>
          </name>
          <xref ref-type="aff" rid="aff0003">
            <sup>3</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>El Hayek</surname>
            <given-names>Samer</given-names>
          </name>
          <xref ref-type="aff" rid="aff0004">
            <sup>4</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9887-072X</contrib-id>
          <name>
            <surname>Zibara</surname>
            <given-names>Kazem</given-names>
          </name>
          <xref ref-type="aff" rid="aff0005">
            <sup>5</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moresco</surname>
            <given-names>Monica</given-names>
          </name>
          <xref ref-type="aff" rid="aff0006">
            <sup>6</sup>
          </xref>
          <xref ref-type="aff" rid="aff0007">
            <sup>7</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1051-0472</contrib-id>
          <name>
            <surname>Plazzi</surname>
            <given-names>Giuseppe</given-names>
          </name>
          <xref ref-type="aff" rid="aff0006">
            <sup>6</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cosentino</surname>
            <given-names>Filomena I I</given-names>
          </name>
          <xref ref-type="aff" rid="aff0008">
            <sup>8</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6937-3065</contrib-id>
          <name>
            <surname>Ferri</surname>
            <given-names>Raffaele</given-names>
          </name>
          <xref ref-type="aff" rid="aff0008">
            <sup>8</sup>
          </xref>
          <xref ref-type="corresp" rid="an0001"/>
        </contrib>
        <aff id="aff0001"><label>1</label><institution>Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina</institution>, <addr-line>Messina</addr-line>, <country>Italy</country></aff>
        <aff id="aff0002"><label>2</label><institution>Faculty of Medicine, American University of Beirut Medical Center</institution>, <addr-line>Beirut</addr-line>, <country>Lebanon</country></aff>
        <aff id="aff0003"><label>3</label><institution>Department of Chemistry and Biochemistry, Texas Tech University</institution>, <addr-line>Lubbock</addr-line>, <addr-line>TX</addr-line>, <addr-line>79409</addr-line>, <country>USA</country></aff>
        <aff id="aff0004"><label>4</label><institution>Department of Psychiatry, American University of Beirut</institution>, <addr-line>Beirut</addr-line>, <country>Lebanon</country></aff>
        <aff id="aff0005"><label>5</label><institution>Department of Biology, Faculty of Sciences-I, PRASE, DSST, Lebanese University</institution>, <addr-line>Beirut</addr-line>, <country>Lebanon</country></aff>
        <aff id="aff0006"><label>6</label><institution>Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna</institution>, <addr-line>Bologna</addr-line>, <country>Italy</country></aff>
        <aff id="aff0007"><label>7</label><institution>IRCCS Istituto delle Scienze Neurologiche di Bologna</institution>, <addr-line>Bologna</addr-line>, <country>Italy</country></aff>
        <aff id="aff0008"><label>8</label><institution>Sleep Research Centre, Oasi Research Institute - IRCCS</institution>, <addr-line>Troina</addr-line>, <country>Italy</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="an0001">Correspondence: Raffaele Ferri <institution>Sleep Research Centre, Oasi Research Institute - IRCCS</institution>, <addr-line>Troina</addr-line>, <addr-line>94018</addr-line>, <country>Italy</country><phone>Tel +39 0935 936111</phone><fax>Fax +39 0935 936231</fax> Email rferri@oasi.en.it</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>6</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2021</year>
      </pub-date>
      <volume>13</volume>
      <fpage>873</fpage>
      <lpage>883</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>3</month>
          <year>2021</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>5</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2021 Mondello et al.</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>Mondello et al.</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref>
          <license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <sec id="s2001">
          <title>Purpose</title>
          <p>We performed comparative proteomic analyses of blood of patients with RLS and healthy individuals aiming to identify potential biomarker and therapeutic target candidate for RLS.</p>
        </sec>
        <sec id="s2002">
          <title>Patients and Methods</title>
          <p>Blood serum samples from 12 patients with a clinical diagnosis of RLS (8 females and 4 males, with a mean age of 68.52 years) and 10 healthy controls (5 females and 5 males, with a mean age of 67.61 years) underwent proteomic profiling by liquid chromatography coupled with tandem mass spectrometry. Pathway analysis incorporating protein–protein interaction networks was carried out to identify pathological processes linked to the differentially expressed proteins.</p>
        </sec>
        <sec id="s2003">
          <title>Results</title>
          <p>We quantified 272 proteins in patients with RLS and healthy controls, of which 243 were shared. Five proteins – apolipoprotein C-II, leucine-rich alpha-2-glycoprotein 1, FLJ92374, extracellular matrix protein 1, and FLJ93143 – were substantially increased in RLS patients, whereas nine proteins – vitamin D-binding protein, FLJ78071, alpha-1-antitrypsin, CD5 antigen-like, haptoglobin, fibrinogen alpha chain, complement factor H-related protein 1, platelet factor 4, and plasma protease C1 inhibitor – were decreased. Bioinformatics analyses revealed that these proteins were linked to 1) inflammatory and immune response, and complement activation, 2) brain-related development, cell aging, and memory disorders, 3) pregnancy and associated complications, 4) myocardial infarction, and 5) reactive oxygen species generation and subsequent diabetes mellitus.</p>
        </sec>
        <sec id="s2004">
          <title>Conclusion</title>
          <p>Our findings shed light on the multifactorial nature of RLS and identified a set of circulating proteins that may have clinical importance as biomarkers and therapeutic targets.</p>
        </sec>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords</title>
        <kwd>idiopathic restless legs syndrome</kwd>
        <kwd>biomarkers</kwd>
        <kwd>LC-MS/MS</kwd>
        <kwd>proteome</kwd>
        <kwd>interactome</kwd>
      </kwd-group>
      <counts>
        <fig-count count="1"/>
        <table-count count="1"/>
        <ref-count count="85"/>
        <page-count count="11"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s0001">
      <title>Introduction</title>
      <p>Restless leg syndrome (RLS)<xref rid="cit0001" ref-type="bibr">1</xref> is a relatively common neurologic sleep-related movement disorder, with a reported prevalence ranging from 5% to 10% in the general population, making it the most common movement disorder and one of the most common sleep disorders.<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0003" ref-type="bibr">3</xref> RLS often impairs sleep and has a significant negative impact on the health-related quality of life;<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0004" ref-type="bibr">4</xref> hypothalamic-pituitary-adrenal system activation in RLS may also contribute to cerebrovascular disease and stroke.<xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0006" ref-type="bibr">6</xref></p>
      <p>Still relatively little is known about the pathophysiology of RLS.<xref rid="cit0007" ref-type="bibr">7</xref>,<xref rid="cit0008" ref-type="bibr">8</xref> Early imaging<xref rid="cit0009" ref-type="bibr">9–11</xref> and pharmacological studies<xref rid="cit0012" ref-type="bibr">12–15</xref> have demonstrated a dysregulation of central dopaminergic neurotransmission, empirically confirmed by the improvement following treatment with dopamine agonists.<xref rid="cit0016" ref-type="bibr">16</xref>,<xref rid="cit0017" ref-type="bibr">17</xref> Nevertheless, objective measures of dopamine function are not clinically available, and results of imaging studies of dopamine receptors are inconsistent and contradictory.<xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0019" ref-type="bibr">19</xref> Human evidence has implied an aberrant central nervous system iron metabolism in the pathophysiology of RLS, though the underlying mechanism remains unclear, and other non-dopaminergic pathways may also play a crucial role.<xref rid="cit0019" ref-type="bibr">19–23</xref></p>
      <p>To date, the diagnosis of RLS primarily relies on its clinical features, while self-administered surveys can be used for screening.<xref rid="cit0024" ref-type="bibr">24</xref> This approach, however, presents important limitations with high risk of misdiagnosis and delays, hampering appropriate patient management and timely initiation of therapeutic interventions.<xref rid="cit0025" ref-type="bibr">25</xref></p>
      <p>Disease states and pathological dysfunctions may be reflected in substantial changes in the concentrations of proteins in the blood, generating a disease-specific molecular signature.<xref rid="cit0026" ref-type="bibr">26</xref>,<xref rid="cit0027" ref-type="bibr">27</xref> Mass spectrometry-based proteomics represent a powerful tool to explore altered cellular proteomes, opening up new avenues for better understanding of disease pathophysiology and for biomarker discovery.<xref rid="cit0028" ref-type="bibr">28–31</xref> Efforts have been made to identify biomarkers using this approach. Nonetheless, research is still in its infancy and data are scarce. Only few proteomic studies were previously conducted, one using cerebrospinal fluid (CSF)<xref rid="cit0032" ref-type="bibr">32</xref> and other blood plasma.<xref rid="cit0033" ref-type="bibr">33–36</xref> The latter represents a better resource for biomarkers, as they should be not only highly sensitive and specific but also easily attainable.<xref rid="cit0037" ref-type="bibr">37</xref></p>
      <p>In this study, we performed comparative proteomic analyses of serum samples of patients with RLS and healthy individuals to identify biomarker and therapeutic target candidate for RLS. We also used bioinformatic analysis to elucidate pathobiological processes and dysregulated pathways that underlie the observed molecular phenotype.</p>
    </sec>
    <sec id="s0002">
      <title>Patients and Methods</title>
      <sec id="s0002-s2001">
        <title>Study Participants</title>
        <p>Patients with a clinical diagnosis of idiopathic RLS were recruited from the Sleep Research Centre of the Oasi Research Institute – IRCCS, Troina (Italy) and the Department of Neurology of the University of Bologna (Italy), between March 2017 and August 2017. Eligibility criteria included diagnosis of RLS and age 18 years or older. All patients underwent physical (including neurological) examination by an experienced physician, and diagnosis was made according to the International RLS Study Group diagnostic criteria<xref rid="cit0001" ref-type="bibr">1</xref> by means of a semi-structured clinical interview and a careful exclusion of RLS mimics. Specifically, a patient was considered to be affected by RLS if she/he met the five standard diagnostic criteria. Exclusion criteria included 1) a sleep disorder diagnosis (other than RLS); 2) neurological or psychiatric diagnosis; 3) major medical disorder; 4) use of any drug or medication for 3 weeks before the analysis; 5) previous iron supplementation. The disease severity was also assessed by means of the International RLS Study Group severity (IRLS) scale<xref rid="cit0038" ref-type="bibr">38</xref>: we only included patients with a moderate disease severity (IRLS &lt;25, range between 15 and 24), most of them were being diagnosed for the first time and all had a disease duration &lt;10 years. None of the patients was affected by iron-deficient anemia and none had ferritin levels &lt;50 µg/L. Healthy participants served as controls.</p>
        <p>The study was approved by the Oasi Research Institute Ethics Committee (no. 2018/07/18/CE-IRCCS-OASI/14). All participants provided written informed consent prior to participation in the study. All procedures were performed in accordance with the 1964 Helsinki declaration and its later amendments.</p>
      </sec>
      <sec id="s0002-s2002">
        <title>Blood Sampling and Materials</title>
        <p>Serum samples were collected between 9 AM and noon. They were processed, aliquoted, and frozen at –80°C according to standardized procedures.<xref rid="cit0039" ref-type="bibr">39</xref> HPLC-gradient water purchased from Avantor Performance Materials (Center Valley, PA, USA) and HPLC-grade acetonitrile (ACN) were obtained from Fisher Scientific (Pittsburgh, PA, USA). Ammonium bicarbonate (ABC), DL-dithiothreitol (DTT) and iodoacetamide (IAA) were produced from Sigma-Aldrich (St. Louis, MO). Formic acid was purchased from TCI America (Portland, OR, USA). Mass-spectrometry-grade Trypsin/Lys-C Mix was obtained from Promega (Madison, WI, USA).</p>
      </sec>
      <sec id="s0002-s2003">
        <title>Depletion of High Abundance Proteins in Serum</title>
        <p>Multiple affinity removal column (4.6×100 mm) was used to deplete the 14 most abundant proteins, namely albumin, IgG, antitrypsin, IgA, transferrin, haptoglobin, fibrinogen, alpha 2-macroglobulin, alpha 1-acid glycoprotein, IgM, apolipoprotein AI, apolipoprotein AII, complement C3 and transthyretin. The affinity column was attached to the Dionex 3000 Ultimate <italic>RS</italic> LC system (Dionex, Sunnyvale, CA, USA) with buffer A (Agilent, Santa Clara, CA, USA) as mobile phase A and buffer B (Agilent, Santa Clara, CA, USA) as mobile phase B. LC gradient stated in the manufacture's handbook was used for the depletion. A 30 µL-aliquot of blood serum of each sample combined with 70 µL of buffer A was subjected to depletion separately. The buffer of depleted blood serum was exchanged into 50 mM ammonium bicarbonate (pH 8.0) using 5KDa MWCO 4 mL spin concentrator from Agilent (Santa Clara, CA, USA) following manufacture’s instruction. The depletion process was necessary to decrease the high dynamic range of serum proteome, thus allowing the identification and quantitation of low abundant proteins.</p>
      </sec>
      <sec id="s0002-s2004">
        <title>Tryptic Digestion</title>
        <p>Prior to tryptic digestion, the protein concentration was determined by the micro BCA protein assay kit following the protocol provided by the Thermo Scientific Pierce (Rockford, IL, USA). A 20-µg aliquot of depleted serum proteins with 50 mM ABC buffer added to 100 µL was transferred to an Eppendorf tube. Thermal denaturation was performed at 80 °C for 20 min. DTT and IAA with concentration of 200 mM was prepared in 50 mM ABC buffer. Proteins were first reduced by adding a 2.5-µL aliquot of DTT solution and incubation at 60 °C for 45 min. Next, the reduced proteins were alkylated by adding a 10-µL aliquot of IAA solution and incubation at 37.5 °C for 45 min. The alkylation reaction was then quenched by adding a second 2.5-µL aliquot of DTT and incubation at 37.5 °C for 30 min. A 0.8-µg aliquot of trypsin was added to the reduced and alkylated sample, and then incubated at 37.5 °C for 18 h. The enzymatic digestion was quenched by adding a 0.5-µL neat formic acid. Prior to liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis, the samples were speed-vacuum dried and resuspended in 2% ACN/0.1% formic acid.</p>
      </sec>
      <sec id="s0002-s2005">
        <title>LC-MS/MS Analysis</title>
        <p>Analysis was performed on a Dionex 3000 Ultimate nano-LC system (Sunnyvale, CA, USA) interfaced to a LTQ OrbitrapVelos mass spectrometer (Thermo Scientific, Waltham, MA, USA) equipped with a nano-ESI source. For each sample, tryptic digests corresponded to 2µg of proteins were subjected to LC-MS/MS analysis. Samples were first online-purified using Thermo Scientific Acclaim PepMap100 C18 pre-column (75 µm × 20 mm, 3 µm, 100 Å). Next, the tryptic digests were separated using Thermo Scientific Acclaim PepMap100 C18 pre-column (75 µm × 150 mm, 2 µm, 100 Å). The separation was achieved at a flow rate of 350 nL/min in 120 min, using following gradient: Solvent B was kept at 5% for the first 10 min, increased from 5% to 20% over 55 min, 20–30% over 25 min, 30–50% over 20 min, 50–80% over 1 min, kept at 80% for 4 min, decreased from 80% to 5% over 1 min and maintained at 5% over 4 min. The solvent A contained 2% ACN, 0.1% FA and 97.9% water, while the solvent B is 0.1% formic acid in ACN.</p>
        <p>The LTQ OrbitrapVelos mass spectrometer was operated in data-dependent acquisition mode with two scan events. The first scan event was a full MS scan of 400–2000 m/z with a resolution of 60,000. The second MS event was a CID MS/MS scan repeated 10 times on 10 most intense ions selected from the first full MS scan with mass resolution of 7,500 and an isolation width of 3 m/z. Normalized collision energy (CE) was set to 35 with and activation Q value of 0.250 and an activation time of 10 ms.</p>
      </sec>
      <sec id="s0002-s2006">
        <title>LC-MS/MS Data Analysis</title>
        <p>The LC-MS/MS data were analyzed by Max Quantversion 2.4 (Matrix Science Inc., Boston, MA). LC-MS/MS data were searched against Swiss Prot human database. Carbamidomethylation of cysteine was set as a fixed modification, while oxidation of methionine was set as a variable modification. The m/z tolerance was set to 6 ppm and 0.5 Da for precursor and fragment ions, respectively, for the identification of peptides. Minimal peptide length was set to 7 with maximum of two missed cleavages. Only proteins with at least two peptides identified were considered. The “Matching-between-runs” function was enabled. Label-free quantification (LFQ) approach was employed and the LFQ intensities were used for subsequent data analysis.</p>
      </sec>
      <sec id="s0002-s2007">
        <title>System Biology Analysis</title>
        <p>For protein interaction and pathway analysis, the Elsevier’s Pathway Studio version 10.0 (Ariadne Genomics/Elsevier) was used to demonstrate relationships among differentially expressed protein candidates using the ResNetdatabase. In this regard, “Subnetwork Enrichment Analysis” (SNEA) algorithm was selected to extract statistically significant altered biological and functional pathways pertaining to each identified set of protein hits.</p>
      </sec>
      <sec id="s0002-s2008">
        <title>Statistical Analysis</title>
        <p>The statistical analysis was performed using Perseus version 1.5.5.0 (Max Planck Institute of Biochemistry, Munich, Germany) and GraphPad Prism 7 (GraphPad Software Company, La Jolla, CA, USA). For both peptide and protein identification, a false discovery rate (FDR) adjusted p-value (ie, q value) threshold of 0.01 was used. For the statistical analysis, SNEA utilizes the Fisher’s statistical test to determine if there are nonrandom associations between two categorical variables organized by specific relationship (protein interaction and biological process). Specifically, SNEA starts by creating a central “seed” from all relevant entities in the database based on their relationship with the seed (eg, binding partners, expression targets, protein modification targets, regulation). The algorithm compares the sub-network distribution to the background distribution using one-sided Mann–Whitney <italic>U</italic>-Test, and calculates a p-value indicating the statistical significance of difference between two distributions. In our analysis, “GenBank” ID and gene symbols from each set were imported to the software to form an experimental data set.</p>
      </sec>
    </sec>
    <sec id="s0003">
      <title>Results</title>
      <sec id="s0003-s2001">
        <title>Differentially Expressed Proteins in Patients with RLS Compared to Healthy Controls</title>
        <p>The study included 12 patients with a clinical diagnosis of RLS (8 females and 4 males, with a mean age of 68.52 years) and 10 healthy controls (5 females and 5 males, with a mean age of 67.61 years). There were no significant differences in age or sex composition between the two groups.</p>
        <p>A total of 272 circulating proteins were identified and quantified (<underline><ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=311801.docx">Supplementary Table S1</ext-link></underline>). Of those, 250 were detected in the healthy controls and 246 in patients with RLS. Among the 243 shared proteins 14 proteins differ considerably, of which 5 were upregulated and 9 were downregulated in RLS compared to healthy controls. <xref rid="t0001" ref-type="table">Table 1</xref> shows the differentially expressed proteins with the biological processes and molecular functions.<table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1</label><caption><p>Table Displaying the Main Characteristics of the Differentially Expressed Proteins in Patients with RLS Compared to Healthy Controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Protein Name</th><th rowspan="1" colspan="1">Biological Process</th><th rowspan="1" colspan="1">Molecular Function</th><th rowspan="1" colspan="1">Gene Name</th><th rowspan="1" colspan="1">Protein ID</th><th rowspan="1" colspan="1">Fold Change</th><th rowspan="1" colspan="1">q-value</th></tr></thead><tbody><tr><td colspan="7" rowspan="1"><bold>Upregulated Proteins</bold></td></tr><tr><td rowspan="1" colspan="1">Apolipoprotein C-II</td><td rowspan="1" colspan="1">Lipid metabolic process</td><td rowspan="1" colspan="1">Binding, enzyme activator activity</td><td rowspan="1" colspan="1"><italic>APOC2</italic></td><td rowspan="1" colspan="1">P02655</td><td rowspan="1" colspan="1">2.26</td><td rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td rowspan="1" colspan="1">Leucine-rich alpha-2-glycoprotein 1</td><td rowspan="1" colspan="1">Cellular process, immune system process</td><td rowspan="1" colspan="1">Binding</td><td rowspan="1" colspan="1"><italic>LRG1</italic></td><td rowspan="1" colspan="1">P02750</td><td rowspan="1" colspan="1">1.97</td><td rowspan="1" colspan="1">0.0005</td></tr><tr><td rowspan="1" colspan="1">FLJ92374, highly similar to <italic>Homo sapiens</italic> C-type lectin domain family 3, member B</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">B2R582</td><td rowspan="1" colspan="1">1.23</td><td rowspan="1" colspan="1">0.0118</td></tr><tr><td rowspan="1" colspan="1">Extracellular matrix protein 1</td><td rowspan="1" colspan="1">Angiogenesis</td><td rowspan="1" colspan="1">Binding, extracellular matrix structural constituent</td><td rowspan="1" colspan="1"><italic>ECM1</italic></td><td rowspan="1" colspan="1">Q16610</td><td rowspan="1" colspan="1">2.07</td><td rowspan="1" colspan="1">0.023</td></tr><tr><td rowspan="1" colspan="1">FLJ93143, highly similar to <italic>Homo sapiens</italic> complement component 7</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">B2R6W1</td><td rowspan="1" colspan="1">1.63</td><td rowspan="1" colspan="1">0.0464</td></tr><tr><td colspan="7" rowspan="1"><bold>Downregulated Proteins</bold></td></tr><tr><td rowspan="1" colspan="1">Vitamin D-binding protein</td><td rowspan="1" colspan="1">Localization</td><td rowspan="1" colspan="1">Binding, transporter activity</td><td rowspan="1" colspan="1"><italic>GC</italic></td><td rowspan="1" colspan="1">P02774</td><td rowspan="1" colspan="1">0.94</td><td rowspan="1" colspan="1">&lt;0.0001</td></tr><tr><td rowspan="1" colspan="1">FLJ78071, highly similar to Human MHC class III complement component C6</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">-</td><td rowspan="1" colspan="1">A8K8Z4</td><td rowspan="1" colspan="1">0.54</td><td rowspan="1" colspan="1">0.0005</td></tr><tr><td rowspan="1" colspan="1">Alpha-1-antitrypsin</td><td rowspan="1" colspan="1">Cellular process, acute phase response</td><td rowspan="1" colspan="1">Binding, catalytic activity, molecular function regulator</td><td rowspan="1" colspan="1"><italic>SERPINA1</italic></td><td rowspan="1" colspan="1">P01009</td><td rowspan="1" colspan="1">0.44</td><td rowspan="1" colspan="1">0.0006</td></tr><tr><td rowspan="1" colspan="1">CD5 antigen-like</td><td rowspan="1" colspan="1">Immune system process, apoptosis</td><td rowspan="1" colspan="1">Receptor activity</td><td rowspan="1" colspan="1"><italic>CD5L</italic></td><td rowspan="1" colspan="1">O43866</td><td rowspan="1" colspan="1">0.73</td><td rowspan="1" colspan="1">0.0018</td></tr><tr><td rowspan="1" colspan="1">Haptoglobin</td><td rowspan="1" colspan="1">Biological regulation, cellular process, response to stimulus</td><td rowspan="1" colspan="1">Binding, antioxidant activity</td><td rowspan="1" colspan="1"><italic>HP</italic></td><td rowspan="1" colspan="1">P00738</td><td rowspan="1" colspan="1">0.14</td><td rowspan="1" colspan="1">0.0051</td></tr><tr><td rowspan="1" colspan="1">Fibrinogen alpha chain</td><td rowspan="1" colspan="1">Cellular process</td><td rowspan="1" colspan="1">Binding, structural molecule activity, extracellular matrix structural constituent</td><td rowspan="1" colspan="1"><italic>FGA</italic></td><td rowspan="1" colspan="1">P02671</td><td rowspan="1" colspan="1">0.57</td><td rowspan="1" colspan="1">0.0216</td></tr><tr><td rowspan="1" colspan="1">Complement factor H-related protein 1</td><td rowspan="1" colspan="1">Immune system process, viral process</td><td rowspan="1" colspan="1">Binding</td><td rowspan="1" colspan="1"><italic>CFHR1</italic></td><td rowspan="1" colspan="1">Q03591</td><td rowspan="1" colspan="1">0.58</td><td rowspan="1" colspan="1">0.0247</td></tr><tr><td rowspan="1" colspan="1">Platelet factor 4</td><td rowspan="1" colspan="1">Immune system process, localization, response to stimulus</td><td rowspan="1" colspan="1">Binding, molecular function regulator, molecular transducer activity</td><td rowspan="1" colspan="1"><italic>PF4</italic></td><td rowspan="1" colspan="1">P02776</td><td rowspan="1" colspan="1">0.59</td><td rowspan="1" colspan="1">0.041</td></tr><tr><td rowspan="1" colspan="1">Plasma protease C1 inhibitor</td><td rowspan="1" colspan="1">Cellular process</td><td rowspan="1" colspan="1">Binding, catalytic activity, molecular function regulator</td><td rowspan="1" colspan="1"><italic>SERPING1</italic></td><td rowspan="1" colspan="1">P05155</td><td rowspan="1" colspan="1">0.73</td><td rowspan="1" colspan="1">0.0453</td></tr></tbody></table></table-wrap>
</p>
      </sec>
      <sec id="s0003-s2002">
        <title>Global Interactome Maps and Enrichment Pathways Analysis for Patients with RLS</title>
        <p>We identified multiple altered pathways when using the 14 identified differentially expressed proteins in the patients with RLS. The interactome networks related to these proteins, along with their associated genes, are presented in <xref ref-type="fig" rid="f0001">Figure 1</xref>.<fig id="f0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Interactome networks describing pathways associated with inflammatory response, immune response, and complement activation (<bold>A</bold>), brain-related development, cell aging, and memory disorders (<bold>B</bold>), myocardial infarction-related pathways (<bold>C</bold>), reactive oxygen species generation and subsequent diabetes mellitus (<bold>D</bold>), and pregnancy-related pathways and their associated complications (<bold>E</bold>), based on the differentially expressed proteins in patients with RLS. Red = upregulated; green = downregulated; mixed color: third party interacting molecule. Interactome network for the differentially expressed genes extracted using the Shortest Path algorithm.</p></caption><graphic content-type="print-only" xlink:href="NSS-13-873-g0001"/></fig></p>
        <p><xref ref-type="fig" rid="f0001">Figure 1A</xref> shows an intricate network of inflammation, associated with inflammatory response, immune response, and complement activation, connecting nine of the identified proteins, namely apolipoprotein C-II (APOC-II), vitamin D-binding protein (DBP), alpha-1-antitrypsin (A<sub>1</sub>AT), CD5 antigen-like (CD5L), haptoglobin (Hp), fibrinogen alpha chain (FGA), complement factor H-related protein 1 (CFHR1), platelet factor 4 (PF4), and plasma protease C1 inhibitor.</p>
        <p><xref ref-type="fig" rid="f0001">Figure 1B</xref> displays a network associated with brain development and memory disorders. In this pathway, the differentially expressed A<sub>1</sub>AT is linked to cell aging, subsequently affecting neuronal development and contributing to the development of memory disorders.</p>
        <p>Similarly, in <xref ref-type="fig" rid="f0001">Figure 1C</xref>, multiple proteins (ie, A<sub>1</sub>AT, Hp, FGA, and plasma protease C1 inhibitor have been directly linked to myocardial infarction, via their interaction with pathways affecting the cardiovascular function and cerebrovascular circulation.</p>
        <p><xref ref-type="fig" rid="f0001">Figure 1D</xref> presents a network associated with diabetes mellitus and its related complications. In this pathway, the differentially expressed APOC-II, A<sub>1</sub>AT, Hp, FGA, PF4, and Plasma protease C1 inhibitor are associated with the generation of reactive oxygen species, contributing to the pathophysiology of diabetes.</p>
        <p>Finally, data in <xref ref-type="fig" rid="f0001">Figure 1E</xref> show the involvement of several differentially expressed proteins (DBP, A<sub>1</sub>AT, Hp, FGA, PF4, and Plasma protease C1 inhibitor in pregnancy and its related complications.</p>
      </sec>
    </sec>
    <sec id="s0004">
      <title>Discussion</title>
      <p>We found 14 differentially expressed proteins in the blood of RLS patients compared to healthy controls. To understand the potential pathobiological and pathogenetic relevance of these proteins in RLS, we used several advanced bioinformatics tools that revealed five independent pathways and networks centered on inflammation/immune response, brain-related development, pregnancy, myocardial infarction, and oxidative stress (<xref ref-type="fig" rid="f0001">Figure 1</xref>). This analysis pointed to a multiplicity and diversity of pathophysiological mechanisms that may underlie and be active in this complex disorder.</p>
      <p>Importantly, serum levels of APOC-II were found to be significantly upregulated in patients with RLS, ultimately increasing the risk of cardiovascular disease.<xref rid="cit0040" ref-type="bibr">40</xref> To date, there is no reported association between APOC-II and RLS; nevertheless, a higher prevalence of hypercholesterolemia has been previously noted in these patients,<xref rid="cit0041" ref-type="bibr">41</xref>,<xref rid="cit0042" ref-type="bibr">42</xref> even if the mechanisms might be complex and influenced by comorbidities.<xref rid="cit0043" ref-type="bibr">43</xref> In a study by Patton et al, proteomic analysis of CSF samples from 5 patients with RLS identified a differential downregulation of another apolipoprotein, APOA-I,<xref rid="cit0032" ref-type="bibr">32</xref> while a recent work investigating serum proteome of 6 patients<xref rid="cit0035" ref-type="bibr">35</xref> reported substantial upregulation of APOH, which is involved in blood coagulation. An association between vascular risk factors of cardiac disease and RLS has previously been established.<xref rid="cit0041" ref-type="bibr">41–43</xref> Our findings provide additional evidence supporting a relationship and shared mechanisms between RLS and cardiovascular disease.</p>
      <p>Another protein that we found substantially increased was leucine-rich alpha-2-glycoprotein 1. This leucine-rich repeat molecule acts as an acute-phase protein and inflammatory marker,<xref rid="cit0044" ref-type="bibr">44</xref> with elevated plasma levels observed in inflammatory diseases.<xref rid="cit0045" ref-type="bibr">45</xref> As such, it has also been proposed as a biomarker for heart failure<xref rid="cit0046" ref-type="bibr">46</xref> and neurodegenerative diseases.<xref rid="cit0047" ref-type="bibr">47</xref> In patients with diabetes mellitus, elevated blood levels of this protein have been strongly associated with albuminuria and progression of diabetic chronic kidney disease.<xref rid="cit0048" ref-type="bibr">48</xref> The association between RLS and diabetes can possibly be directional, with both conditions exacerbating each other.</p>
      <p>Our proteomic evaluations also showed higher expression of serum extracellular matrix protein (ECM1) in patients with RLS. ECM1 plays an integral role in the positive and negative regulation of hepcidin, particularly in a tumor setting.<xref rid="cit0049" ref-type="bibr">49</xref> Hepcidin, a peptide hormone that negatively regulates iron efflux,<xref rid="cit0050" ref-type="bibr">50</xref> is a potential prognostic biomarker for RLS. In fact, one study comparing 65 females with primary RLS to matched controls showed higher serum hepcidin quantified via mass spectrometry; in particular, hepcidin levels reflected RLS clinical severity in a U-shaped curve relationship.<xref rid="cit0036" ref-type="bibr">36</xref>,<xref rid="cit0051" ref-type="bibr">51</xref> This reemphasizes the primary role of iron and its metabolism in the pathophysiology of RLS.</p>
      <p>From our analysis, among differentially downregulated proteins in the serum of patients with RLS, it appears relevant to have found changes in DBP. Proteomic analysis of CSF from patients with RLS identified also a differential expression of DBP, yet with a characteristic upregulation postulated to reflect the activation of immune cascades in the central nervous system.<xref rid="cit0032" ref-type="bibr">32</xref> Likewise, upregulation of DBP was reported in the serum of a very small sample of RLS patients.<xref rid="cit0035" ref-type="bibr">35</xref> Along with its role in regulating vitamin D metabolites, DBP scavenges toxins released during cell injury<xref rid="cit0052" ref-type="bibr">52</xref> and modulates the immune response.<xref rid="cit0053" ref-type="bibr">53</xref> In addition, variations of its level of expression in the CSF has been associated with multiple neurodegenerative disorders, including Parkinson’s disease and multiple sclerosis.<xref rid="cit0054" ref-type="bibr">54</xref>,<xref rid="cit0055" ref-type="bibr">55</xref> Moreover, vitamin D has been postulated to contribute to the etiology of RLS and several studies performed comparative analysis of vitamin D plasma levels in patients with RLS and healthy controls. Balaban et al<xref rid="cit0056" ref-type="bibr">56</xref> have reported lower levels of serum 25-hydroxyvitamin D in 36 female patients with RLS compared to controls. In a cross-sectional study of 57 patients with vitamin D deficiency and 45 healthy controls, RLS incidence was found to be higher in the former group.<xref rid="cit0057" ref-type="bibr">57</xref> In another study of 155 matched patients divided according to their serum 25-hydroxyvitamin D level and compared for the presence of RLS diagnostic criteria, vitamin D deficiency was significantly associated with the presence of RLS.<xref rid="cit0058" ref-type="bibr">58</xref> Similarly, in a study involving 201 participants, the odds ratio of the development of RLS was 4.24 for those with a vitamin D deficiency (level &lt;50 nmol/L).<xref rid="cit0059" ref-type="bibr">59</xref> These several lines of evidence support the idea that iron deficiency in RLS might affect central dopaminergic activity via a vitamin-D mediated pathway.<xref rid="cit0056" ref-type="bibr">56</xref> Moreover, in terms of vitamin-D related genes, individuals with the rs731236AA genotype or carriers of the rs731236A allelic variant of the vitamin D receptor gene had a decreased risk of RLS, while those with the rs731236GG genotype had higher severity of RLS.<xref rid="cit0060" ref-type="bibr">60</xref> Our findings, therefore, further support the pluripotential role of vitamin D and its receptors in the pathophysiology of RLS. The observed evidence of a dysregulated Vitamin D pathway is of further interest in consideration of the emerging data indicating that RLS during pregnancy might be linked to Vitamin D deficiency, and is associated with adverse pregnancy outcomes.<xref rid="cit0061" ref-type="bibr">61–63</xref> This is a critical area for future investigation.</p>
      <p>In line with the results of the proteomic analysis by Bellei et al,<xref rid="cit0033" ref-type="bibr">33</xref> in our study, the concentration of A<sub>1</sub>AT was substantial in RLS patients. A<sub>1</sub>AT has pleiotropic effects, having been shown an association with pathways of inflammation, memory disorders, pregnancy, and cardiovascular disease as well as activation of antioxidant enzymes, suppression of oxidation stress, and decrease apoptosis.<xref rid="cit0064" ref-type="bibr">64</xref> In a recent systematic review of blood proteomic studies of Alzheimer’s disease, A<sub>1</sub>AT was identified as a candidate biomarker.<xref rid="cit0065" ref-type="bibr">65</xref> In pre-eclampsia, it functions as a protective factor: this is mediated by an inhibition of p38 mitogen-activated protein kinase p38MAPK signaling pathway<xref rid="cit0066" ref-type="bibr">66</xref> and activation of Smad2 and Id4 genes,<xref rid="cit0067" ref-type="bibr">67</xref> allowing maintenance of the vascular function during pregnancy. In terms of cardiac risk, the literature pinpoints a correlation between A<sub>1</sub>AT and cardiovascular disorders.<xref rid="cit0068" ref-type="bibr">68</xref> As A<sub>1</sub>AT has a protective role in regulating vascular smooth muscle cells and decreasing vascular damage, a low serum level is associated with increased risk of developing arteriosclerosis.<xref rid="cit0069" ref-type="bibr">69</xref></p>
      <p>Another protein we found significantly downregulated in patients with RLS is Hp, an inflammation acute-phase protein with immunomodulatory and anti-inflammatory properties.<xref rid="cit0070" ref-type="bibr">70</xref> By binding to free hemoglobin, it prevents the iron-driven formation of reactive oxygen species and oxidative tissue damage,<xref rid="cit0071" ref-type="bibr">71</xref> and elevated Hp levels are observed in chronic inflammatory conditions associated with increased oxidative stress.<xref rid="cit0072" ref-type="bibr">72</xref>,<xref rid="cit0073" ref-type="bibr">73</xref> In addition, Hp has been stated as a marker for diabetes mellitus and its complications.<xref rid="cit0074" ref-type="bibr">74</xref> This is prominently denoted in <xref ref-type="fig" rid="f0001">Figure 1A</xref> and <xref ref-type="fig" rid="f0001">D</xref>. In the study by Bellei et al,<xref rid="cit0033" ref-type="bibr">33</xref> Hp was characteristically found to be upregulated; The discrepant results may result from the inclusion in this study of RLS patients on medications, which might have affected the results of the proteomic analysis. In our study, the differential regulation of Hp might be also related to a chronic inflammatory milieu involved in the modulation of RLS.<xref rid="cit0075" ref-type="bibr">75</xref> This certainly needs to be better studied in the future, also by taking into consideration the influential role of the presence of a high number of periodic leg movements during sleep in these patients.<xref rid="cit0076" ref-type="bibr">76</xref> We also found another protein, CFHR1, to be downregulated in patients with RLS, in agreement with the previous findings by Bellei et al.<xref rid="cit0033" ref-type="bibr">33</xref> The complement system directly regulates inflammatory processes and maintains associated homeostasis;<xref rid="cit0077" ref-type="bibr">77</xref> thus, any alteration in this system is potentially able to worsen inflammation. This further reinforces the importance to better define the role of inflammation in RLS, also because it might represent an important target for the development of new therapeutic strategies.</p>
      <p>Plasma protease C1 inhibitor levels were also significantly low in our patients with RLS compared to controls. By regulating C1 complex and inhibiting chymotrypsin and kallikrein, plasma protease C1 inhibitor plays a crucial role in fibrinolysis and downregulation, again, of inflammation.<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0079" ref-type="bibr">79</xref> SERPING1 has been reported to be a sensitive and specific (&gt;80%) biomarker for diagnosing type I diabetes mellitus (<xref ref-type="fig" rid="f0001">Figure 1D</xref>).<xref rid="cit0080" ref-type="bibr">80</xref> It was also found to be significantly associated with IGF binding protein 1, a biomarker of type II diabetes mellitus, with processes related to the immune function, oxidative stress, and cellular death.<xref rid="cit0081" ref-type="bibr">81</xref></p>
      <p>The other identified differentially expressed proteins, CD5L, FGA, and PF4, are associated with inflammation, neuropathology, complications of pregnancy, cardiovascular dysfunction, and diabetes mellitus. More specifically, CD5L has been demonstrated to be involved in inflammation, kidney diseases, cardiovascular diseases, diabetes, and cancers,<xref rid="cit0082" ref-type="bibr">82</xref> PF4 has been reported to mediate inflammation,<xref rid="cit0083" ref-type="bibr">83</xref> while FGA has been related to trauma, pregnancy, or tissue inflammation and clotting-related disorders.<xref rid="cit0084" ref-type="bibr">84</xref> Noticeably, it is necessary to take into consideration that FGA is one of the proteins depleted by the MARS14 column. The detection of FGA in this study was because the depletion efficiency of FGA was not perfect.<xref rid="cit0085" ref-type="bibr">85</xref> Hence, despite we observed a significant change in abundance of FGA among the different groups, this difference might have been caused by the bias introduced by the depletion steps. More investigations need to be performed for the expressions of FGA in RLS in future studies.</p>
      <p>Interestingly, we identified three proteins: protein that is highly similar to homo sapiens C-type lectin domain family 3 (FLJ92374), protein that is highly similar to homo sapiens complement component 7 (FLJ93143), and protein that is highly similar to human MHC class III complement component C6 (FLJ78071), that have not been proven at proteomic levels before. According to UniProt database (<underline><ext-link ext-link-type="uri" xlink:href="http://www.uniprot.org">www.uniprot.org</ext-link></underline>), and NCBI gene bank (<underline><ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</ext-link></underline>), the existence of these proteins was only based on the experimental evidence at transcript level. The up-regulations of FLJ92374 and FLJ93143 and the down-regulation of FLJ78071 were observed in RLS samples, indicating the necessity of investigation of these proteins in further studies.</p>
    </sec>
    <sec id="s0005">
      <title>Limitations and Strengths</title>
      <p>Our study has some limitations. Due to the limited number of participants in each group, our findings should be interpreted with caution. We accounted for this drawback by adopting stringent recruitment criteria, with participants being off medications in order to avoid potential confounding effects on the proteomic analysis. Nonetheless, further analyses in larger cohorts applying complementary validation techniques and exploring the influence of factors that may contribute to proteome changes are necessary. Another limitation is that the low number of patients recruited precludes correlation analysis with the disease severity. It will be important to study this clinical characteristic, which coupled with an analysis of the degree of fold change in protein expression, might indicate a potential value to objectively assess the neurobiological severity of RLS.</p>
    </sec>
    <sec id="s0006">
      <title>Conclusion</title>
      <p>In summary, we have performed an in-depth rigorous blood-based proteome profiling of non-treated patients with RLS, providing initial evidence of a detectable disease-specific molecular phenotype associated with inflammation, oxidative stress, cardiovascular disease, and metabolic dysfunction. Altogether, our data shed new light on the multifactorial nature of RLS, indicating that multiple and diverse pathophysiological mechanisms are involved in this complex disorder. This ultimately suggests that future therapeutic and intervention strategies for patients with RLS may need to be pleiotropic and multitargeted, in order to be clinically effective.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>This was not an industry-supported study. This work was performed at the Oasi Research Institute – IRCCS, Troina, Italy and at the Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas, 79409, USA. This study was partially supported by a fund from the Italian Ministry of Health “Ricerca Corrente” (RC n. 2634472) (F.I.I.C., R.F.).</p>
    </ack>
    <sec id="s0007">
      <title>Data Sharing Statement</title>
      <p>The authors confirm that the data supporting the findings of this study are available within the article and/or <underline><ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/get_supplementary_file.php?f=311801.docx">Table S1</ext-link></underline>.</p>
    </sec>
    <sec id="s0008" sec-type="COI-statement">
      <title>Disclosure</title>
      <p>Dr Giuseppe Plazzi reports personal fees from Jazz Pharmaceuticals, IDORSIA, Takeda, UCB, and Bioprojet, outside the submitted work. The authors report no other potential conflicts of interest in this work.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="cit0001">
        <label>1.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Allen</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Picchietti</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Garcia-Borreguero</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>8</issue>):<fpage>860</fpage>–<lpage>873</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.03.025</pub-id><pub-id pub-id-type="pmid">25023924</pub-id></mixed-citation>
      </ref>
      <ref id="cit0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Allen</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Walters</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Restless legs syndrome prevalence and impact: REST general population study</article-title>. <source><italic toggle="yes">Arch Intern Med</italic></source>. <year>2005</year>;<volume>165</volume>(<issue>11</issue>):<fpage>1286</fpage>–<lpage>1292</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinte.165.11.1286</pub-id><pub-id pub-id-type="pmid">15956009</pub-id></mixed-citation>
      </ref>
      <ref id="cit0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tison</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Crochard</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Leger</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Bouee</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lainey</surname>
<given-names>E</given-names></string-name>, <string-name><surname>El Hasnaoui</surname>
<given-names>A</given-names></string-name>. <article-title>Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2005</year>;<volume>65</volume>(<issue>2</issue>):<fpage>239</fpage>–<lpage>246</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.wnl.0000168910.48309.4a</pub-id><pub-id pub-id-type="pmid">16043793</pub-id></mixed-citation>
      </ref>
      <ref id="cit0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Abetz</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Allen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Follet</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Evaluating the quality of life of patients with restless legs syndrome</article-title>. <source><italic toggle="yes">Clin Ther</italic></source>. <year>2004</year>;<volume>26</volume>(<issue>6</issue>):<fpage>925</fpage>–<lpage>935</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0149-2918(04)90136-1</pub-id><pub-id pub-id-type="pmid">15262463</pub-id></mixed-citation>
      </ref>
      <ref id="cit0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Walters</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Rye</surname>
<given-names>DB</given-names></string-name>. <article-title>Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2009</year>;<volume>32</volume>(<issue>5</issue>):<fpage>589</fpage>–<lpage>597</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/32.5.589</pub-id><pub-id pub-id-type="pmid">19480225</pub-id></mixed-citation>
      </ref>
      <ref id="cit0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Schilling</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Schredl</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Strobl</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Deuschle</surname>
<given-names>M</given-names></string-name>. <article-title>Restless legs syndrome: evidence for nocturnal hypothalamic-pituitary-adrenal system activation</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2010</year>;<volume>25</volume>(<issue>8</issue>):<fpage>1047</fpage>–<lpage>1052</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.23026</pub-id><pub-id pub-id-type="pmid">20535825</pub-id></mixed-citation>
      </ref>
      <ref id="cit0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Winkelmann</surname>
<given-names>J</given-names></string-name>. <article-title>Restless legs syndrome: update on pathogenesis</article-title>. <source><italic toggle="yes">Curr Opin Pulm Med</italic></source>. <year>2013</year>;<volume>19</volume>(<issue>6</issue>):<fpage>594</fpage>–<lpage>600</lpage>. doi:<pub-id pub-id-type="doi">10.1097/MCP.0b013e328365ab07</pub-id><pub-id pub-id-type="pmid">24048084</pub-id></mixed-citation>
      </ref>
      <ref id="cit0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Earley</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Connor</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Garcia-Borreguero</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Altered brain iron homeostasis and dopaminergic function in restless legs syndrome (Willis-Ekbom disease)</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>11</issue>):<fpage>1288</fpage>–<lpage>1301</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.05.009</pub-id><pub-id pub-id-type="pmid">25201131</pub-id></mixed-citation>
      </ref>
      <ref id="cit0009">
        <label>9.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Staedt</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Stoppe</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kogler</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus)</article-title>. <source><italic toggle="yes">J Neural Transm Gen Sect</italic></source>. <year>1993</year>;<volume>93</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1007/BF01244940</pub-id><pub-id pub-id-type="pmid">8103994</pub-id></mixed-citation>
      </ref>
      <ref id="cit0010">
        <label>10.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Turjanski</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Lees</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Brooks</surname>
<given-names>DJ</given-names></string-name>. <article-title>Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>1999</year>;<volume>52</volume>(<issue>5</issue>):<fpage>932</fpage>–<lpage>937</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.52.5.932</pub-id><pub-id pub-id-type="pmid">10102408</pub-id></mixed-citation>
      </ref>
      <ref id="cit0011">
        <label>11.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Michaud</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Soucy</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Chabli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lavigne</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>. <article-title>SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2002</year>;<volume>249</volume>(<issue>2</issue>):<fpage>164</fpage>–<lpage>170</lpage>. doi:<pub-id pub-id-type="doi">10.1007/PL00007859</pub-id><pub-id pub-id-type="pmid">11985381</pub-id></mixed-citation>
      </ref>
      <ref id="cit0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Brodeur</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Godbout</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Marinier</surname>
<given-names>R</given-names></string-name>. <article-title>Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>1988</year>;<volume>38</volume>(<issue>12</issue>):<fpage>1845</fpage>–<lpage>1848</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.38.12.1845</pub-id><pub-id pub-id-type="pmid">3057399</pub-id></mixed-citation>
      </ref>
      <ref id="cit0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Earley</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Yaffee</surname>
<given-names>JB</given-names></string-name>, <string-name><surname>Allen</surname>
<given-names>RP</given-names></string-name>. <article-title>Randomized, double-blind, placebo-controlled trial of pergolide in restless legs syndrome</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>1998</year>;<volume>51</volume>(<issue>6</issue>):<fpage>1599</fpage>–<lpage>1602</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.51.6.1599</pub-id><pub-id pub-id-type="pmid">9855508</pub-id></mixed-citation>
      </ref>
      <ref id="cit0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wetter</surname>
<given-names>TC</given-names></string-name>, <string-name><surname>Stiasny</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Winkelmann</surname>
<given-names>J</given-names></string-name>, et al. <article-title>A randomized controlled study of pergolide in patients with restless legs syndrome</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>1999</year>;<volume>52</volume>(<issue>5</issue>):<fpage>944</fpage>–<lpage>950</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.52.5.944</pub-id><pub-id pub-id-type="pmid">10102410</pub-id></mixed-citation>
      </ref>
      <ref id="cit0015">
        <label>15.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Montplaisir</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Nicolas</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Denesle</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Gomez-Mancilla</surname>
<given-names>B</given-names></string-name>. <article-title>Restless legs syndrome improved by pramipexole: a double-blind randomized trial</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>1999</year>;<volume>52</volume>(<issue>5</issue>):<fpage>938</fpage>–<lpage>943</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.52.5.938</pub-id><pub-id pub-id-type="pmid">10102409</pub-id></mixed-citation>
      </ref>
      <ref id="cit0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Silber</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Becker</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Earley</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Garcia-Borreguero</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ondo</surname>
<given-names>WG</given-names></string-name>. <article-title>Medical advisory board of the Willis-Ekbom disease F. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome</article-title>. <source><italic toggle="yes">Mayo Clin Proc</italic></source>. <year>2013</year>;<volume>88</volume>(<issue>9</issue>):<fpage>977</fpage>–<lpage>986</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.mayocp.2013.06.016</pub-id><pub-id pub-id-type="pmid">24001490</pub-id></mixed-citation>
      </ref>
      <ref id="cit0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Garcia-Borreguero</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kohnen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Silber</surname>
<given-names>MH</given-names></string-name>, et al. <article-title>The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>7</issue>):<fpage>675</fpage>–<lpage>684</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2013.05.016</pub-id><pub-id pub-id-type="pmid">23859128</pub-id></mixed-citation>
      </ref>
      <ref id="cit0018">
        <label>18.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Allen</surname>
<given-names>RP</given-names></string-name>. <article-title>Controversies and challenges in defining the etiology and pathophysiology of restless legs syndrome</article-title>. <source><italic toggle="yes">Am J Med</italic></source>. <year>2007</year>;<volume>120</volume>(<issue>1 Suppl 1</issue>):<fpage>S13</fpage>–<lpage>S21</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.amjmed.2006.11.003</pub-id></mixed-citation>
      </ref>
      <ref id="cit0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Earley</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Kuwabara</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>DF</given-names></string-name>, et al. <article-title>The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2011</year>;<volume>34</volume>(<issue>3</issue>):<fpage>341</fpage>–<lpage>347</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/34.3.341</pub-id><pub-id pub-id-type="pmid">21358851</pub-id></mixed-citation>
      </ref>
      <ref id="cit0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Allen</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Barker</surname>
<given-names>PB</given-names></string-name>, <string-name><surname>Wehrl</surname>
<given-names>FW</given-names></string-name>, <string-name><surname>Song</surname>
<given-names>HK</given-names></string-name>, <string-name><surname>Earley</surname>
<given-names>CJ</given-names></string-name>. <article-title>MRI measurement of brain iron in patients with restless legs syndrome</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2001</year>;<volume>56</volume>(<issue>2</issue>):<fpage>263</fpage>–<lpage>265</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.56.2.263</pub-id><pub-id pub-id-type="pmid">11160969</pub-id></mixed-citation>
      </ref>
      <ref id="cit0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Earley</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Connor</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Beard</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Malecki</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Epstein</surname>
<given-names>DK</given-names></string-name>, <string-name><surname>Allen</surname>
<given-names>RP</given-names></string-name>. <article-title>Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2000</year>;<volume>54</volume>(<issue>8</issue>):<fpage>1698</fpage>–<lpage>1700</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.54.8.1698</pub-id><pub-id pub-id-type="pmid">10762522</pub-id></mixed-citation>
      </ref>
      <ref id="cit0022">
        <label>22.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Connor</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Boyer</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Menzies</surname>
<given-names>SL</given-names></string-name>, et al. <article-title>Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2003</year>;<volume>61</volume>(<issue>3</issue>):<fpage>304</fpage>–<lpage>309</lpage>. doi:<pub-id pub-id-type="doi">10.1212/01.WNL.0000078887.16593.12</pub-id><pub-id pub-id-type="pmid">12913188</pub-id></mixed-citation>
      </ref>
      <ref id="cit0023">
        <label>23.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Allen</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Earley</surname>
<given-names>CJ</given-names></string-name>, et al. <article-title>Brain iron deficiency in idiopathic restless legs syndrome measured by quantitative magnetic susceptibility at 7 tesla</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2016</year>;<volume>22</volume>:<fpage>75</fpage>–<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2016.05.001</pub-id><pub-id pub-id-type="pmid">27544840</pub-id></mixed-citation>
      </ref>
      <ref id="cit0024">
        <label>24.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Allen</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Picchietti</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hening</surname>
<given-names>WA</given-names></string-name>, et al. <article-title>Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2003</year>;<volume>4</volume>(<issue>2</issue>):<fpage>101</fpage>–<lpage>119</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1389-9457(03)00010-8</pub-id><pub-id pub-id-type="pmid">14592341</pub-id></mixed-citation>
      </ref>
      <ref id="cit0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nagandla</surname>
<given-names>K</given-names></string-name>, <string-name><surname>De</surname>
<given-names>S</given-names></string-name>. <article-title>Restless legs syndrome: pathophysiology and modern management</article-title>. <source><italic toggle="yes">Postgrad Med J</italic></source>. <year>2013</year>;<volume>89</volume>(<issue>1053</issue>):<fpage>402</fpage>–<lpage>410</lpage>. doi:<pub-id pub-id-type="doi">10.1136/postgradmedj-2012-131634</pub-id><pub-id pub-id-type="pmid">23524988</pub-id></mixed-citation>
      </ref>
      <ref id="cit0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fawaz</surname>
<given-names>CN</given-names></string-name>, <string-name><surname>Makki</surname>
<given-names>IS</given-names></string-name>, <string-name><surname>Kazan</surname>
<given-names>JM</given-names></string-name>, et al. <article-title>Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research</article-title>. <source><italic toggle="yes">Expert Rev Proteomics</italic></source>. <year>2015</year>;<volume>12</volume>(<issue>6</issue>):<fpage>637</fpage>–<lpage>650</lpage>. doi:<pub-id pub-id-type="doi">10.1586/14789450.2015.1099435</pub-id><pub-id pub-id-type="pmid">26479122</pub-id></mixed-citation>
      </ref>
      <ref id="cit0027">
        <label>27.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jaber</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Aouad</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Al Medawar</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Role of systems biology in brain injury biomarker discovery: neuroproteomics application</article-title>. <source><italic toggle="yes">Methods Mol Biol</italic></source>. <year>2016</year>;<volume>1462</volume>:<fpage>157</fpage>–<lpage>174</lpage>.<pub-id pub-id-type="pmid">27604718</pub-id></mixed-citation>
      </ref>
      <ref id="cit0028">
        <label>28.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kim</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Pinto</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Getnet</surname>
<given-names>D</given-names></string-name>, et al. <article-title>A draft map of the human proteome</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2014</year>;<volume>509</volume>(<issue>7502</issue>):<fpage>575</fpage>–<lpage>581</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature13302</pub-id><pub-id pub-id-type="pmid">24870542</pub-id></mixed-citation>
      </ref>
      <ref id="cit0029">
        <label>29.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Mondello</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kobeissy</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mechref</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Novel biomarker signatures for idiopathic REM sleep behavior disorder: a proteomic and system biology approach</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2018</year>;<volume>91</volume>(<issue>18</issue>):<fpage>e1710</fpage>–<lpage>e1715</lpage>. doi:<pub-id pub-id-type="doi">10.1212/WNL.0000000000006439</pub-id><pub-id pub-id-type="pmid">30258025</pub-id></mixed-citation>
      </ref>
      <ref id="cit0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Azar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Hasan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Younes</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Biofluid proteomics and biomarkers in traumatic brain injury</article-title>. <source><italic toggle="yes">Methods Mol Biol</italic></source>. <year>2017</year>;<volume>1598</volume>:<fpage>45</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">28508357</pub-id></mixed-citation>
      </ref>
      <ref id="cit0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Mondello</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Muller</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Jeromin</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Streeter</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Hayes</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>KK</given-names></string-name>. <article-title>Blood-based diagnostics of traumatic brain injuries</article-title>. <source><italic toggle="yes">Expert Rev Mol Diagn</italic></source>. <year>2011</year>;<volume>11</volume>(<issue>1</issue>):<fpage>65</fpage>–<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.1586/erm.10.104</pub-id><pub-id pub-id-type="pmid">21171922</pub-id></mixed-citation>
      </ref>
      <ref id="cit0032">
        <label>32.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Patton</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Cho</surname>
<given-names>YW</given-names></string-name>, <string-name><surname>Clardy</surname>
<given-names>TW</given-names></string-name>, <string-name><surname>Allen</surname>
<given-names>RP</given-names></string-name>, <string-name><surname>Earley</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Connor</surname>
<given-names>JR</given-names></string-name>. <article-title>Proteomic analysis of the cerebrospinal fluid of patients with restless legs syndrome/Willis-Ekbom disease</article-title>. <source><italic toggle="yes">Fluids Barriers CNS</italic></source>. <year>2013</year>;<volume>10</volume>(<issue>1</issue>):<fpage>20</fpage>. doi:<pub-id pub-id-type="doi">10.1186/2045-8118-10-20</pub-id><pub-id pub-id-type="pmid">23758918</pub-id></mixed-citation>
      </ref>
      <ref id="cit0033">
        <label>33.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bellei</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Monari</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Ozben</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Discovery of restless legs syndrome plasmatic biomarkers by proteomic analysis</article-title>. <source><italic toggle="yes">Brain Behav</italic></source>. <year>2018</year>;<volume>8</volume>(<issue>10</issue>):<fpage>e01062</fpage>. doi:<pub-id pub-id-type="doi">10.1002/brb3.1062</pub-id><pub-id pub-id-type="pmid">30244532</pub-id></mixed-citation>
      </ref>
      <ref id="cit0034">
        <label>34.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bellei</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Bergamini</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Monari</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Evaluation of potential cardiovascular risk protein biomarkers in high severity restless legs syndrome</article-title>. <source><italic toggle="yes">J Neural Transm</italic></source>. <year>2019</year>;<volume>126</volume>(<issue>10</issue>):<fpage>1313</fpage>–<lpage>1320</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00702-019-02051-7</pub-id><pub-id pub-id-type="pmid">31338581</pub-id></mixed-citation>
      </ref>
      <ref id="cit0035">
        <label>35.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Shin</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>H</given-names></string-name>, et al. <article-title>Bioinformatic analysis of proteomic data for iron, inflammation, and hypoxic pathways in restless legs syndrome</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2020</year>;<volume>75</volume>:<fpage>448</fpage>–<lpage>455</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2020.09.002</pub-id><pub-id pub-id-type="pmid">32992101</pub-id></mixed-citation>
      </ref>
      <ref id="cit0036">
        <label>36.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chenini</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Delaby</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Rassu</surname>
<given-names>AL</given-names></string-name>, et al. <article-title>Hepcidin and ferritin levels in restless legs syndrome: a case-control study</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>11914</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-68851-0</pub-id><pub-id pub-id-type="pmid">32681031</pub-id></mixed-citation>
      </ref>
      <ref id="cit0037">
        <label>37.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kohn</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Azad</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Annunziata</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Dhamoon</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Whiteley</surname>
<given-names>G</given-names></string-name>. <article-title>Proteomics as a tool for biomarker discovery</article-title>. <source><italic toggle="yes">Dis Markers</italic></source>. <year>2007</year>;<volume>23</volume>(<issue>5–6</issue>):<fpage>411</fpage>–<lpage>417</lpage>. doi:<pub-id pub-id-type="doi">10.1155/2007/967023</pub-id><pub-id pub-id-type="pmid">18057524</pub-id></mixed-citation>
      </ref>
      <ref id="cit0038">
        <label>38.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Walters</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>LeBrocq</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Dhar</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2003</year>;<volume>4</volume>(<issue>2</issue>):<fpage>121</fpage>–<lpage>132</lpage>.<pub-id pub-id-type="pmid">14592342</pub-id></mixed-citation>
      </ref>
      <ref id="cit0039">
        <label>39.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Mondello</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kobeissy</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Vestri</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hayes</surname>
<given-names>RL</given-names></string-name>, <string-name><surname>Kochanek</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Berger</surname>
<given-names>RP</given-names></string-name>. <article-title>Serum concentrations of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein after pediatric traumatic brain injury</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2016</year>;<volume>6</volume>:<fpage>28203</fpage>. doi:<pub-id pub-id-type="doi">10.1038/srep28203</pub-id><pub-id pub-id-type="pmid">27319802</pub-id></mixed-citation>
      </ref>
      <ref id="cit0040">
        <label>40.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kei</surname>
<given-names>AA</given-names></string-name>, <string-name><surname>Filippatos</surname>
<given-names>TD</given-names></string-name>, <string-name><surname>Tsimihodimos</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Elisaf</surname>
<given-names>MS</given-names></string-name>. <article-title>A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease</article-title>. <source><italic toggle="yes">Metabolism</italic></source>. <year>2012</year>;<volume>61</volume>(<issue>7</issue>):<fpage>906</fpage>–<lpage>921</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.metabol.2011.12.002</pub-id><pub-id pub-id-type="pmid">22304839</pub-id></mixed-citation>
      </ref>
      <ref id="cit0041">
        <label>41.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Winter</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Berger</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Glynn</surname>
<given-names>RJ</given-names></string-name>, et al. <article-title>Vascular risk factors, cardiovascular disease, and restless legs syndrome in men</article-title>. <source><italic toggle="yes">Am J Med</italic></source>. <year>2013</year>;<volume>126</volume>(<issue>3</issue>):<page-range>228–235, 235 e221–222</page-range>. doi:<pub-id pub-id-type="doi">10.1016/j.amjmed.2012.06.039</pub-id></mixed-citation>
      </ref>
      <ref id="cit0042">
        <label>42.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Schlesinger</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Erikh</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Avizohar</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Sprecher</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Yarnitsky</surname>
<given-names>D</given-names></string-name>. <article-title>Cardiovascular risk factors in restless legs syndrome</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2009</year>;<volume>24</volume>(<issue>11</issue>):<fpage>1587</fpage>–<lpage>1592</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.22486</pub-id><pub-id pub-id-type="pmid">19526583</pub-id></mixed-citation>
      </ref>
      <ref id="cit0043">
        <label>43.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Trenkwalder</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Allen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Hogl</surname>
<given-names>B</given-names></string-name>, et al. <article-title>Comorbidities, treatment, and pathophysiology in restless legs syndrome</article-title>. <source><italic toggle="yes">Lancet Neurol</italic></source>. <year>2018</year>;<volume>17</volume>(<issue>11</issue>):<fpage>994</fpage>–<lpage>1005</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1474-4422(18)30311-9</pub-id><pub-id pub-id-type="pmid">30244828</pub-id></mixed-citation>
      </ref>
      <ref id="cit0044">
        <label>44.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Shirai</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Hirano</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Ohkura</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Ikeda</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Inoue</surname>
<given-names>S</given-names></string-name>. <article-title>Up-regulation of the expression of leucine-rich alpha(2)-glycoprotein in hepatocytes by the mediators of acute-phase response</article-title>. <source><italic toggle="yes">Biochem Biophys Res Commun</italic></source>. <year>2009</year>;<volume>382</volume>(<issue>4</issue>):<fpage>776</fpage>–<lpage>779</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2009.03.104</pub-id><pub-id pub-id-type="pmid">19324010</pub-id></mixed-citation>
      </ref>
      <ref id="cit0045">
        <label>45.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Serada</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fujimoto</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ogata</surname>
<given-names>A</given-names></string-name>, et al. <article-title>iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases</article-title>. <source><italic toggle="yes">Ann Rheum Dis</italic></source>. <year>2010</year>;<volume>69</volume>(<issue>4</issue>):<fpage>770</fpage>–<lpage>774</lpage>. doi:<pub-id pub-id-type="doi">10.1136/ard.2009.118919</pub-id><pub-id pub-id-type="pmid">19854709</pub-id></mixed-citation>
      </ref>
      <ref id="cit0046">
        <label>46.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Watson</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Ledwidge</surname>
<given-names>MT</given-names></string-name>, <string-name><surname>Phelan</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Proteomic analysis of coronary sinus serum reveals leucine-rich alpha 2-glycoprotein as a novel biomarker of ventricular dysfunction and heart failure</article-title>. <source><italic toggle="yes">Circ Heart Fail</italic></source>. <year>2011</year>;<volume>4</volume>(<issue>2</issue>):<fpage>188</fpage>–<lpage>197</lpage>. doi:<pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.110.952200</pub-id><pub-id pub-id-type="pmid">21282491</pub-id></mixed-citation>
      </ref>
      <ref id="cit0047">
        <label>47.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Miyajima</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nakajima</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Motoi</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Leucine-rich alpha 2-glycoprotein is a novel biomarker of neurodegenerative disease in human cerebrospinal fluid and causes neurodegeneration in mouse cerebral cortex</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2013</year>;<volume>8</volume>(<issue>9</issue>):<fpage>e74453</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0074453</pub-id><pub-id pub-id-type="pmid">24058569</pub-id></mixed-citation>
      </ref>
      <ref id="cit0048">
        <label>48.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Liu</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Pek</surname>
<given-names>SLT</given-names></string-name>, <string-name><surname>Ang</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Tavintharan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>SC</given-names></string-name>, <collab>study SD</collab>. <article-title>Plasma leucine-rich alpha-2-glycoprotein 1 predicts rapid eGFR decline and albuminuria progression in type 2 diabetes mellitus</article-title>. <source><italic toggle="yes">J Clin Endocrinol Metab</italic></source>. <year>2017</year>;<volume>102</volume>(<issue>10</issue>):<fpage>3683</fpage>–<lpage>3691</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2017-00930</pub-id><pub-id pub-id-type="pmid">28973352</pub-id></mixed-citation>
      </ref>
      <ref id="cit0049">
        <label>49.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Blanchette</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Tesfay</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kita</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Claffey</surname>
<given-names>KP</given-names></string-name>, <string-name><surname>Torti</surname>
<given-names>FM</given-names></string-name>, <string-name><surname>Torti</surname>
<given-names>SV</given-names></string-name>. <article-title>A novel role for the extracellular matrix in regulation of hepcidin in breast cancer spheroids</article-title>. <source><italic toggle="yes">FASEB J</italic></source>. <year>2016</year>;<volume>30</volume>(<issue>1_supplement</issue>):<fpage>1099</fpage>–<lpage>1107</lpage>.</mixed-citation>
      </ref>
      <ref id="cit0050">
        <label>50.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ganz</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Nemeth</surname>
<given-names>E</given-names></string-name>. <article-title>Hepcidin and iron homeostasis</article-title>. <source><italic toggle="yes">Biochim Biophys Acta</italic></source>. <year>2012</year>;<volume>1823</volume>(<issue>9</issue>):<fpage>1434</fpage>–<lpage>1443</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbamcr.2012.01.014</pub-id><pub-id pub-id-type="pmid">22306005</pub-id></mixed-citation>
      </ref>
      <ref id="cit0051">
        <label>51.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Chenini</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Vialaret</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Association between serum hepcidin level and restless legs syndrome</article-title>. <source><italic toggle="yes">Mov Disord</italic></source>. <year>2018</year>;<volume>33</volume>(<issue>4</issue>):<fpage>618</fpage>–<lpage>627</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mds.27287</pub-id><pub-id pub-id-type="pmid">29418021</pub-id></mixed-citation>
      </ref>
      <ref id="cit0052">
        <label>52.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Speeckaert</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Delanghe</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Taes</surname>
<given-names>YE</given-names></string-name>. <article-title>Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism</article-title>. <source><italic toggle="yes">Clin Chim Acta</italic></source>. <year>2006</year>;<volume>372</volume>(<issue>1–2</issue>):<fpage>33</fpage>–<lpage>42</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cca.2006.03.011</pub-id><pub-id pub-id-type="pmid">16697362</pub-id></mixed-citation>
      </ref>
      <ref id="cit0053">
        <label>53.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gomme</surname>
<given-names>PT</given-names></string-name>, <string-name><surname>Bertolini</surname>
<given-names>J</given-names></string-name>. <article-title>Therapeutic potential of vitamin D-binding protein</article-title>. <source><italic toggle="yes">Trends Biotechnol</italic></source>. <year>2004</year>;<volume>22</volume>(<issue>7</issue>):<fpage>340</fpage>–<lpage>345</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tibtech.2004.05.001</pub-id><pub-id pub-id-type="pmid">15245906</pub-id></mixed-citation>
      </ref>
      <ref id="cit0054">
        <label>54.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Qin</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Qin</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>S</given-names></string-name>. <article-title>Alteration of DBP levels in CSF of patients with MS by proteomics analysis</article-title>. <source><italic toggle="yes">Cell Mol Neurobiol</italic></source>. <year>2009</year>;<volume>29</volume>(<issue>2</issue>):<fpage>203</fpage>–<lpage>210</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10571-008-9312-z</pub-id><pub-id pub-id-type="pmid">18807170</pub-id></mixed-citation>
      </ref>
      <ref id="cit0055">
        <label>55.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Sokal</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Peskind</surname>
<given-names>ER</given-names></string-name>, et al. <article-title>CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases</article-title>. <source><italic toggle="yes">Am J Clin Pathol</italic></source>. <year>2008</year>;<volume>129</volume>(<issue>4</issue>):<fpage>526</fpage>–<lpage>529</lpage>. doi:<pub-id pub-id-type="doi">10.1309/W01Y0B808EMEH12L</pub-id><pub-id pub-id-type="pmid">18343778</pub-id></mixed-citation>
      </ref>
      <ref id="cit0056">
        <label>56.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Balaban</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Yildiz</surname>
<given-names>OK</given-names></string-name>, <string-name><surname>Cil</surname>
<given-names>G</given-names></string-name>, et al. <article-title>Serum 25-hydroxyvitamin D levels in restless legs syndrome patients</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2012</year>;<volume>13</volume>(<issue>7</issue>):<fpage>953</fpage>–<lpage>957</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2012.04.009</pub-id><pub-id pub-id-type="pmid">22704399</pub-id></mixed-citation>
      </ref>
      <ref id="cit0057">
        <label>57.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cakir</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Dogan</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Subasi</surname>
<given-names>V</given-names></string-name>, et al. <article-title>An evaluation of sleep quality and the prevalence of restless leg syndrome in vitamin D deficiency</article-title>. <source><italic toggle="yes">Acta Neurol Belg</italic></source>. <year>2015</year>;<volume>115</volume>(<issue>4</issue>):<fpage>623</fpage>–<lpage>627</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13760-015-0474-4</pub-id><pub-id pub-id-type="pmid">25904436</pub-id></mixed-citation>
      </ref>
      <ref id="cit0058">
        <label>58.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Oran</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Unsal</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Albayrak</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Possible association between vitamin D deficiency and restless legs syndrome</article-title>. <source><italic toggle="yes">Neuropsychiatr Dis Treat</italic></source>. <year>2014</year>;<volume>10</volume>:<fpage>953</fpage>–<lpage>958</lpage>. doi:<pub-id pub-id-type="doi">10.2147/NDT.S63599</pub-id><pub-id pub-id-type="pmid">24899811</pub-id></mixed-citation>
      </ref>
      <ref id="cit0059">
        <label>59.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wali</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Alsafadi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Abaalkhail</surname>
<given-names>B</given-names></string-name>, et al. <article-title>The association between vitamin D level and restless legs syndrome: a Population-Based Case-Control Study</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2018</year>;<volume>14</volume>(<issue>4</issue>):<fpage>557</fpage>–<lpage>564</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.7044</pub-id><pub-id pub-id-type="pmid">29609719</pub-id></mixed-citation>
      </ref>
      <ref id="cit0060">
        <label>60.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jimenez-Jimenez</surname>
<given-names>FJ</given-names></string-name>, <string-name><surname>Garcia-Martin</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Alonso-Navarro</surname>
<given-names>H</given-names></string-name>, et al. <article-title>Association between vitamin D receptor rs731236 (Taq1) polymorphism and risk for restless legs syndrome in the Spanish caucasian population</article-title>. <source><italic toggle="yes">Medicine</italic></source>. <year>2015</year>;<volume>94</volume>(<issue>47</issue>):<fpage>e2125</fpage>. doi:<pub-id pub-id-type="doi">10.1097/MD.0000000000002125</pub-id><pub-id pub-id-type="pmid">26632733</pub-id></mixed-citation>
      </ref>
      <ref id="cit0061">
        <label>61.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Almeneessie</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Alyousefi</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Alzahrani</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Prevalence of restless legs syndrome among pregnant women: a case-control study</article-title>. <source><italic toggle="yes">Ann Thorac Med</italic></source>. <year>2020</year>;<volume>15</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.4103/atm.ATM_206_19</pub-id><pub-id pub-id-type="pmid">32002041</pub-id></mixed-citation>
      </ref>
      <ref id="cit0062">
        <label>62.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Picchietti</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Hensley</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Bainbridge</surname>
<given-names>JL</given-names></string-name>, et al. <article-title>Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2015</year>;<volume>22</volume>:<fpage>64</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">25553600</pub-id></mixed-citation>
      </ref>
      <ref id="cit0063">
        <label>63.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gupta</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Dhyani</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kendzerska</surname>
<given-names>T</given-names></string-name>, et al. <article-title>Restless legs syndrome and pregnancy: prevalence, possible pathophysiological mechanisms and treatment</article-title>. <source><italic toggle="yes">Acta Neurol Scand</italic></source>. <year>2016</year>;<volume>133</volume>(<issue>5</issue>):<fpage>320</fpage>–<lpage>329</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ane.12520</pub-id><pub-id pub-id-type="pmid">26482928</pub-id></mixed-citation>
      </ref>
      <ref id="cit0064">
        <label>64.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Feng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>Q</given-names></string-name>, et al. <article-title>Cytoprotective role of alpha-1 antitrypsin in vascular endothelial cell under hypoxia/reoxygenation condition</article-title>. <source><italic toggle="yes">J Cardiovasc Pharmacol</italic></source>. <year>2015</year>;<volume>66</volume>(<issue>1</issue>):<fpage>96</fpage>–<lpage>107</lpage>. doi:<pub-id pub-id-type="doi">10.1097/FJC.0000000000000250</pub-id><pub-id pub-id-type="pmid">25815674</pub-id></mixed-citation>
      </ref>
      <ref id="cit0065">
        <label>65.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kiddle</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Sattlecker</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Proitsi</surname>
<given-names>P</given-names></string-name>, et al. <article-title>Candidate blood proteome markers of alzheimer’s disease onset and progression: a systematic review and replication study</article-title>. <source><italic toggle="yes">J Alzheimers Dis</italic></source>. <year>2014</year>;<volume>38</volume>(<issue>3</issue>):<fpage>515</fpage>–<lpage>531</lpage>. doi:<pub-id pub-id-type="doi">10.3233/JAD-130380</pub-id><pub-id pub-id-type="pmid">24121966</pub-id></mixed-citation>
      </ref>
      <ref id="cit0066">
        <label>66.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Feng</surname>
<given-names>YL</given-names></string-name>, <string-name><surname>Yin</surname>
<given-names>YX</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Alpha-1-antitrypsin suppresses oxidative stress in preeclampsia by inhibiting the p38MAPK signaling pathway: an in vivo and in vitro study</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2017</year>;<volume>12</volume>(<issue>3</issue>):<fpage>e0173711</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0173711</pub-id><pub-id pub-id-type="pmid">28358847</pub-id></mixed-citation>
      </ref>
      <ref id="cit0067">
        <label>67.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Feng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Alpha-1-antitrypsin functions as a protective factor in preeclampsia through activating Smad2 and inhibitor of DNA binding 4</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2017</year>;<volume>8</volume>(<issue>68</issue>):<fpage>113002</fpage>–<lpage>113012</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.22949</pub-id><pub-id pub-id-type="pmid">29348884</pub-id></mixed-citation>
      </ref>
      <ref id="cit0068">
        <label>68.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fahndrich</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Biertz</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Karch</surname>
<given-names>A</given-names></string-name>, et al. <article-title>Cardiovascular risk in patients with alpha-1-antitrypsin deficiency</article-title>. <source><italic toggle="yes">Respir Res</italic></source>. <year>2017</year>;<volume>18</volume>(<issue>1</issue>):<fpage>171</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12931-017-0655-1</pub-id><pub-id pub-id-type="pmid">28915894</pub-id></mixed-citation>
      </ref>
      <ref id="cit0069">
        <label>69.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Duckers</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Shale</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Stockley</surname>
<given-names>RA</given-names></string-name>, et al. <article-title>Cardiovascular and musculskeletal co-morbidities in patients with alpha 1 antitrypsin deficiency</article-title>. <source><italic toggle="yes">Respir Res</italic></source>. <year>2010</year>;<volume>11</volume>:<fpage>173</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1465-9921-11-173</pub-id><pub-id pub-id-type="pmid">21138571</pub-id></mixed-citation>
      </ref>
      <ref id="cit0070">
        <label>70.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gabay</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Kushner</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Epstein</surname>
<given-names>FH</given-names></string-name>. <article-title>Acute-phase proteins and other systemic responses to inflammation</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>1999</year>;<volume>340</volume>(<issue>6</issue>):<fpage>448</fpage>–<lpage>454</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJM199902113400607</pub-id><pub-id pub-id-type="pmid">9971870</pub-id></mixed-citation>
      </ref>
      <ref id="cit0071">
        <label>71.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lim</surname>
<given-names>SK</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>SK</given-names></string-name>, et al. <article-title>Increased susceptibility in Hp knockout mice during acute hemolysis</article-title>. <source><italic toggle="yes">Blood</italic></source>. <year>1998</year>;<volume>92</volume>(<issue>6</issue>):<fpage>1870</fpage>–<lpage>1877</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood.V92.6.1870</pub-id><pub-id pub-id-type="pmid">9731043</pub-id></mixed-citation>
      </ref>
      <ref id="cit0072">
        <label>72.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nakhoul</surname>
<given-names>FM</given-names></string-name>, <string-name><surname>Miller-Lotan</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Awaad</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Asleh</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Levy</surname>
<given-names>AP</given-names></string-name>. <article-title>Hypothesis--haptoglobin genotype and diabetic nephropathy</article-title>. <source><italic toggle="yes">Nat Clin Pract Nephrol</italic></source>. <year>2007</year>;<volume>3</volume>(<issue>6</issue>):<fpage>339</fpage>–<lpage>344</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ncpneph0467</pub-id><pub-id pub-id-type="pmid">17525716</pub-id></mixed-citation>
      </ref>
      <ref id="cit0073">
        <label>73.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Quaye</surname>
<given-names>IK</given-names></string-name>. <article-title>Haptoglobin, inflammation and disease</article-title>. <source><italic toggle="yes">Trans R Soc Trop Med Hyg</italic></source>. <year>2008</year>;<volume>102</volume>(<issue>8</issue>):<fpage>735</fpage>–<lpage>742</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.trstmh.2008.04.010</pub-id><pub-id pub-id-type="pmid">18486167</pub-id></mixed-citation>
      </ref>
      <ref id="cit0074">
        <label>74.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kruger</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Tam</surname>
<given-names>SW</given-names></string-name>, et al. <article-title>Haptoglobin as an early serum biomarker of virus-induced autoimmune type 1 diabetes in biobreeding diabetes resistant and LEW1.WR1 rats</article-title>. <source><italic toggle="yes">Exp Biol Med (Maywood)</italic></source>. <year>2010</year>;<volume>235</volume>(<issue>11</issue>):<fpage>1328</fpage>–<lpage>1337</lpage>. doi:<pub-id pub-id-type="doi">10.1258/ebm.2010.010150</pub-id><pub-id pub-id-type="pmid">20975081</pub-id></mixed-citation>
      </ref>
      <ref id="cit0075">
        <label>75.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Varim</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Acar</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Uyanik</surname>
<given-names>MS</given-names></string-name>, et al. <article-title>Association between the neutrophil-to-lymphocyte ratio, a new marker of systemic inflammation, and restless legs syndrome</article-title>. <source><italic toggle="yes">Singapore Med J</italic></source>. <year>2016</year>;<volume>57</volume>(<issue>9</issue>):<fpage>514</fpage>–<lpage>516</lpage>. doi:<pub-id pub-id-type="doi">10.11622/smedj.2016154</pub-id><pub-id pub-id-type="pmid">27662970</pub-id></mixed-citation>
      </ref>
      <ref id="cit0076">
        <label>76.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Trotti</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Rye</surname>
<given-names>DB</given-names></string-name>, <string-name><surname>De Staercke</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hooper</surname>
<given-names>WC</given-names></string-name>, <string-name><surname>Quyyumi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bliwise</surname>
<given-names>DL</given-names></string-name>. <article-title>Elevated C-reactive protein is associated with severe periodic leg movements of sleep in patients with restless legs syndrome</article-title>. <source><italic toggle="yes">Brain Behav Immun</italic></source>. <year>2012</year>;<volume>26</volume>(<issue>8</issue>):<fpage>1239</fpage>–<lpage>1243</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbi.2012.06.003</pub-id><pub-id pub-id-type="pmid">22750520</pub-id></mixed-citation>
      </ref>
      <ref id="cit0077">
        <label>77.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ricklin</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Hajishengallis</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lambris</surname>
<given-names>JD</given-names></string-name>. <article-title>Complement: a key system for immune surveillance and homeostasis</article-title>. <source><italic toggle="yes">Nat Immunol</italic></source>. <year>2010</year>;<volume>11</volume>(<issue>9</issue>):<fpage>785</fpage>–<lpage>797</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ni.1923</pub-id><pub-id pub-id-type="pmid">20720586</pub-id></mixed-citation>
      </ref>
      <ref id="cit0078">
        <label>78.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Davis</surname>
<given-names>AE</given-names>
<suffix>3rd</suffix></string-name>, <string-name><surname>Mejia</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>F</given-names></string-name>. <article-title>Biological activities of C1 inhibitor</article-title>. <source><italic toggle="yes">Mol Immunol</italic></source>. <year>2008</year>;<volume>45</volume>(<issue>16</issue>):<fpage>4057</fpage>–<lpage>4063</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molimm.2008.06.028</pub-id><pub-id pub-id-type="pmid">18674818</pub-id></mixed-citation>
      </ref>
      <ref id="cit0079">
        <label>79.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Stoermer</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Morrison</surname>
<given-names>TE</given-names></string-name>. <article-title>Complement and viral pathogenesis</article-title>. <source><italic toggle="yes">Virology</italic></source>. <year>2011</year>;<volume>411</volume>(<issue>2</issue>):<fpage>362</fpage>–<lpage>373</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.virol.2010.12.045</pub-id><pub-id pub-id-type="pmid">21292294</pub-id></mixed-citation>
      </ref>
      <ref id="cit0080">
        <label>80.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Zhang</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Fillmore</surname>
<given-names>TL</given-names></string-name>, <string-name><surname>Schepmoes</surname>
<given-names>AA</given-names></string-name>, et al. <article-title>Serum proteomics reveals systemic dysregulation of innate immunity in type 1 diabetes</article-title>. <source><italic toggle="yes">J Exp Med</italic></source>. <year>2013</year>;<volume>210</volume>(<issue>1</issue>):<fpage>191</fpage>–<lpage>203</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.20111843</pub-id><pub-id pub-id-type="pmid">23277452</pub-id></mixed-citation>
      </ref>
      <ref id="cit0081">
        <label>81.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ahluwalia</surname>
<given-names>TS</given-names></string-name>, <string-name><surname>Allin</surname>
<given-names>KH</given-names></string-name>, <string-name><surname>Sandholt</surname>
<given-names>CH</given-names></string-name>, et al. <article-title>Discovery of coding genetic variants influencing diabetes-related serum biomarkers and their impact on risk of type 2 diabetes</article-title>. <source><italic toggle="yes">J Clin Endocrinol Metab</italic></source>. <year>2015</year>;<volume>100</volume>(<issue>4</issue>):<fpage>E664</fpage>–<lpage>E671</lpage>. doi:<pub-id pub-id-type="doi">10.1210/jc.2014-3677</pub-id><pub-id pub-id-type="pmid">25599387</pub-id></mixed-citation>
      </ref>
      <ref id="cit0082">
        <label>82.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sanjurjo</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Aran</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Roher</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Valledor</surname>
<given-names>AF</given-names></string-name>, <string-name><surname>Sarrias</surname>
<given-names>MR</given-names></string-name>. <article-title>AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease</article-title>. <source><italic toggle="yes">J Leukoc Biol</italic></source>. <year>2015</year>;<volume>98</volume>(<issue>2</issue>):<fpage>173</fpage>–<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1189/jlb.3RU0215-074R</pub-id><pub-id pub-id-type="pmid">26048980</pub-id></mixed-citation>
      </ref>
      <ref id="cit0083">
        <label>83.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Shi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Morrell</surname>
<given-names>CN</given-names></string-name>. <article-title>Platelets as initiators and mediators of inflammation at the vessel wall</article-title>. <source><italic toggle="yes">Thromb Res</italic></source>. <year>2011</year>;<volume>127</volume>(<issue>5</issue>):<fpage>387</fpage>–<lpage>390</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.thromres.2010.10.019</pub-id><pub-id pub-id-type="pmid">21094986</pub-id></mixed-citation>
      </ref>
      <ref id="cit0084">
        <label>84.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chapman</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Dogan</surname>
<given-names>A</given-names></string-name>. <article-title>Fibrinogen alpha amyloidosis: insights from proteomics</article-title>. <source><italic toggle="yes">Expert Rev Proteomics</italic></source>. <year>2019</year>;<volume>16</volume>(<issue>9</issue>):<fpage>783</fpage>–<lpage>793</lpage>. doi:<pub-id pub-id-type="doi">10.1080/14789450.2019.1659137</pub-id><pub-id pub-id-type="pmid">31443619</pub-id></mixed-citation>
      </ref>
      <ref id="cit0085">
        <label>85.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Palstrom</surname>
<given-names>NB</given-names></string-name>, <string-name><surname>Rasmussen</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Beck</surname>
<given-names>HC</given-names></string-name>. <article-title>Affinity capture enrichment versus affinity depletion: a comparison of strategies for increasing coverage of low-abundant human plasma proteins</article-title>. <source><italic toggle="yes">Int J Mol Sci</italic></source>. <year>2020</year>;<volume>21</volume>(<issue>16</issue>):<fpage>5903</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms21165903</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
